Allergic bronchopulmonary aspergillosis--a clinical review.

Allergic Bronchopulmonary Aspergillosis (ABPA) was first described by Hinson and colleagues in 1952. ABPA is a hypersensitivity disorder induced by a fungus Aspergillus and affects non-immunocompromised patients. The diagnosis is based on the presence of a combination of clinical, biological and radiological criteria. The treatment is based on oral corticosteroids for 6-8 weeks at acute phase or exacerbation and Itraconazole is now recommended and validated at a dose of 200 mg/day for 16 weeks.